LeMaitre Vascular, Inc.

NASDAQ:LMAT

Medical - Instruments & Supplies

Healthcare
$75.58 +1.74%

+$1.60 today

Market cap
$1.73B
Beta
0.52
P/E (TTM)
34.3
EPS (TTM)
$2.74
Dividend yield
0.96%
52W Low $79.01High $118.01

Volume 0.22M

Average 0.26M

LMAT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

LeMaitre Vascular, Inc.NASDAQ: LMAT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $2.09M rose 2.2% year over year, ahead of the -17.5% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +23.3% a year.

Context

  • Stock-based compensation amounted to 3.1% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +2.2% holds above the trailing-twelve-month pace of -17.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.09M— QoQ
Last fiscal yearDec 2025
$7.83M+19.2% YoY
LTMMar 2026
$5.78M-17.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year+19.2%——
3-year CAGR+23.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7.83M USD
Year-over-year change
+19.2%
4-year CAGR
+22.5%

Stock-Based Compensation vs competitors

How LMAT compares with its peers on the latest reported figures

  • LMAT's LTM Mar 2026 stock-based compensation of $5.78M is the smallest of the 8 companies compared; the peer median is $45.39M.
  • Its year-over-year change of -17.5% is the 6th highest of 8, against a peer median of +5.7%.
  • Stock-based compensation amounts to 2.3% of revenue for LMAT, versus a peer median of 1.8%.
LMAT Competitors Peer median
Stock-Based Compensation for LMAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$496M +14.8%+8.8%1.3%
BSXBoston Scientific CorporationLTM Jun 2026$166M +5.7%+10.8%0.8%
PENPenumbra, Inc.LTM Jun 2026$59.5M +16.5%—4.0%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$45.39M +5.4%+34.1%2.8%
TFXTeleflex IncorporatedLTM Jun 2026$20.21M -33.5%—0.8%
ANGOAngioDynamics, Inc.LTM Feb 2026$11.69M +16.5%-3.0%3.7%
AORTArtivion, Inc.LTM Mar 2026$8.41M -44.1%+25.5%1.8%
LMATLeMaitre Vascular, Inc.LTM Mar 2026$5.78M -17.5%+23.3%2.3%
Peer median (excluding LMAT) $45.39M+5.7%+10.8%1.8%

Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.91M20.64M30.11M44.04M57.73M
Depreciation & Amortization11.07M9.43M9.52M9.67M10.42M
Deferred Income Tax79K(182K)783K(451K)2.31M
Stock-Based Compensation3.48M4.17M5.32M6.57M7.83M
Change in Working Capital(9.96M)(13.4M)(11.25M)(20.1M)(1.75M)
Accounts Receivables(818K)(3.53M)(3.14M)(6.42M)(2.95M)
Inventory(5.49M)(7.42M)(9.79M)(10.57M)(7.22M)
Accounts Payables(1.73M)645K4.6M(779K)4.2M
Other Working Capital(1.93M)(3.1M)(2.92M)(2.33M)4.22M
Other Non-Cash Items3.53M4.72M2.28M4.4M4.71M
Operating Cash Flow35.1M25.38M36.75M44.12M81.25M
Capital Expenditures(4.88M)(3.23M)(7.27M)(6.96M)(6.78M)
Acquisitions (Net)00(899K)0(1.9M)
Purchases of Investments(59.19M)(8M)(16.55M)(277.94M)(641.33M)
Sales of Investments3M0084.78M585.07M
Other Investing Activities0858K000
Investing Cash Flow(61.08M)(10.37M)(24.72M)(200.12M)(64.94M)
Debt Repayment(39M)00169.27M0
Common Stock Issued63.24M3.47M6.17M6.44M6.82M
Common Stock Repurchased00000
Dividends Paid(9.34M)(10.99M)(12.45M)(14.38M)(18.11M)
Other Financing Activities(1.2M)(1.71M)(853K)(3.23M)(3.25M)
Financing Cash Flow13.7M(9.23M)(7.13M)158.1M(14.54M)
Effect of Forex Changes(637K)(494K)230K(765K)864K
Net Change in Cash(12.91M)5.28M5.14M1.34M2.63M
Free Cash Flow30.22M22.15M29.49M37.16M74.47M

LeMaitre Vascular, Inc.

NASDAQ:LMAT

Intrinsic Alpha fair value

Locked

Current Price

$75.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.